Top ACC news story articles of 2022 included news about ACC's new clinical documents – including the new heart failure guideline, new aortic disease guideline and an expert consensus decision pathway on nonstatin therapies – health policy news about the 2023 Medicare Physician Fee Schedule rule, research published in the JACC Journals about Paxlovid, the new Global Burden of CVD issue, and more.

Top 2022 ACC Clinical Documents

• New ACC, AHA, HFSA Guideline Updates Recommendations For Managing HF
  • Heart Failure Guideline Hub
• New ACC/AHA Guideline Address Diagnosis, Management of Aortic Disease
  • Aortic Disease Guideline Hub
• ACC Issues Clinical Guidance on CV Consequences of COVID-19
• New Expert Consensus Decision Pathway Addresses Use of Newer Nonstatin Therapies For Managing LDL-C in ASCVD Patients
• ACC Expert Consensus Decision Pathway Addresses Integrating ASCVD and Multimorbidity Treatment
• ACC Expert Consensus Decision Pathway Focuses on Evaluation and Disposition of Acute Chest Pain in the ED
• ACC Health Policy Statement Outlines Strategies to Address Bias, Discrimination, Bullying and Harassment in the Workplace
• New ACC Health Policy Statement Offers Solutions For Career Flexibility in Cardiology

Top 2022 Advocacy News Stories

• CMS Releases Final 2023 Medicare Physician Fee Schedule Rule
• Overview of Changes For CPT E/M Codes Starting in 2023

Top 2022 JACC News Stories

• COVID-19 Drug Paxlovid May Interact With Common CV Medications
  • ACC's COVID-19 Hub
• Higher Olive Oil Intake May Be Associated With Lower Risk of CVD Mortality
• Special JACC Issue Tracks Latest Trends in Global Burden of CVD

Top 2022 Meeting Coverage News Stories

ACC.22

• Studies Finds Drinking Two to Three Cups of Coffee a Day May Benefit the Heart
• VALOR-HCM: Mavacamten Significantly Reduces Need For Surgical Intervention in Patients With Obstructive HCM
• Efficacy, Safety of Mavacamten in Treating Obstructive HCM Holds Up in EXPLORER-LTE Cohort of MAVA-LTE Study
  • ACC.22 Meeting Coverage Page

ESC Congress 2022

• PANTHER: P2Y12 Inhibitor Monotherapy vs. Aspirin in Patients With CAD
• DELIVER: Dapagliflozin Lowered Risk of Worsening HF, Death in Patients With HFmrEF, HFpEF
• FRAME-AMI: FFR vs. Angiography-Guided PCI in Patient With AMI, Multivessel Disease?
  • ESC Congress 2022 Meeting Coverage Page

AHA 2022

• SPORT: Rosuvastatin vs. Placebo and Six Common Supplements in Lowering LDL-C in Patients at Risk For ASCVD
  • AHA 2022 Meeting Coverage Page

Clinical Topics: Cardiovascular Care Team, COVID-19 Hub, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Vascular Medicine, Lipid Metabolism, Statins, Acute Heart Failure, Interventions and Imaging, Interventions and Vascular Medicine, Angiography, Nuclear Imaging, Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD), Cardiac Surgery, Cardio-Oncology, Congenital Heart Disease and Pediatric Cardiology, Geriatric Cardiology, Noninvasive Imaging, Pericardial Disease, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Sports and Exercise Cardiology, Stable Ischemic Heart Disease, Valvular Heart Disease, Diabetes and Cardiometabolic Disease

Keywords: COVID-19, Cardiovascular Diseases, Rosuvastatin Calcium, Heart Failure, Coffee, Consensus, Olive Oil, Aspirin, Multimorbidity, Percutaneous Coronary Intervention, Fractional Flow Reserve, Myocardial, Medicare, Stroke Volume, Cardiology, Workplace, Physicians, Fee Schedules, Aortic Diseases, Angiography

< Back to Listings